Head & Neck Cancers | Specialty

How BLU-667 Has Changed the Treatment Landscape

October 18th 2019

ESMO 2019 LIBRETTO-001 Trial Updates

October 18th 2019

LOXO-292 in Patients With RET-Fusion Lung Cancer

October 18th 2019

LIBRETTO-001 Regimen Overview

October 18th 2019

RET Testing in Papillary and Medullary Thyroid Cancer

October 18th 2019

The Importance of NGS Testing

October 18th 2019

RET Treatment: Novel Compounds to Replace Current TKIs

October 18th 2019

Multikinase TKIs for NSCLC and Medullary Thyroid Cancer

October 18th 2019

RET Fusion, Point Mutation, and Signaling

October 18th 2019

Why RET Alteration is an Attractive Target for Therapy

October 18th 2019

Dr. Bourhis on the Rationale to Explore Debio 1143 in Head and Neck Cancer

October 17th 2019

Jean Bourhis, MD, PhD, Radiation Oncology, Centre Hospitalier Universitaire Vaudois, discusses the rationale to explore Debio 1143 in patients with head and neck cancer.

Dr. Gross on Neoadjuvant Cemiplimab in Head and Neck CSCC

October 12th 2019

Neil D. Gross, MD, FACS, discusses a phase II study of neoadjuvant cemiplimab in patients with stage III/IV cutaneous squamous cell carcinoma of the head and neck.

Dr. Saba Discusses Ongoing Research in Head and Neck Cancer

October 11th 2019

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses ongoing research in head and neck cancer.

Dr. Bourhis on Results of the Phase II Trial With Debio 1143 in Head and Neck Cancer

October 10th 2019

Jean Bourhis, MD, PhD, Radiation Oncology, Centre Hospitalier Universitaire Vaudois, discusses the results of a phase II trial evaluating the addition of Debio 1143 to concurrent high-dose cisplatin and chemoradiation in high-risk patients with locally advanced squamous cell carcinoma of the head and neck.

Selpercatinib Shows Strong ORR in Thyroid Cancer, FDA Submission Expected

September 29th 2019

The highly selective RET inhibitor selpercatinib (formally LOXO-292) demonstrated robust objective response rates for patients with RET-mutant medullary thyroid cancer and in those with other RET fusion-positive thyroid cancer.

OncLive Community Discussion to Center on De-Intensification Strategies in OPSCC

September 9th 2019

The question of what the accepted therapeutic strategies for de-intensification in low-risk, HPV-related oropharyngeal squamous cell carcinoma are will be debated in an upcoming discussion.

Molecular Testing Enhances Decision-Making Process in Thyroid Cancer of Indeterminate Malignancy

September 7th 2019

In thyroid cancer, molecular diagnostic tests enable oncologists to evaluate thyroid nodules with atypical, suspicious, or indeterminate fine-needle aspiration cytology to determine the best course of treatment based on cytopathological result.

Metformin Plus Chemoradiation Induces Antitumorigenic Immune Response in HNSCC

September 6th 2019

Vidhya Karivedu, MD, fellow/resident at the University of Cincinnati College of Medicine, discusses the antitumorigenic immune response seen with the combination of metformin and chemoradiation in patients with locally advanced head and neck squamous cell carcinoma.

Data Show Potential Impact of Shared Decision Making With RAI Therapy in Thyroid Cancer

August 29th 2019

Patients with differentiated thyroid cancer who were felt to not have a choice in receiving radioactive iodine treatment reportedly had lower satisfaction with the treatment decision, suggesting a need for increased shared decision making between physicians and patients.

Study Suggests Role for Anti-PD-1/PD-L1 Agents in Advanced Thyroid Cancer

August 29th 2019

Among patients with medullary thyroid cancer, PD-L1 positive status is linked to more aggressive clinicopathological features and predictive of structural and biochemical recurrences.